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Background: HIV and SIV defeat antiviral proteins by usurping Cullin-RING E3 ubiquitin ligases (CRLs) and likely
influence other cellular processes through these as well. HIV-2 viral protein X (Vpx) engages the cullin4-containing
CRL4 complex to deplete the antiviral protein SAMHD1. Vif expressed by HIV-1 and HIV-2 taps a cullin5 ubiquitin
ligase complex to mark the antiviral protein APOBEC3G for destruction. Viral Protein R of HIV-1 (Vpr) assembles with
the CRL4 ubiquitin ligase complex to deplete uracil-N-glycosylase2 (UNG2). Covalent attachment of the ubiquitin-like
protein side-chain NEDD8 functionally activates cullins which are common to all of these processes.
Results: The requirement for neddylation in HIV-1 and HIV-2 infectivity was tested in the presence of APOBEC3G and
SAMHD1 respectively. Further the need for neddylation in HIV-1 Vpr-mediated depletion of UNG2 was probed. Treatment
with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation
of cullin4A (CUL4A). The inhibitor hindered HIV-1 infection in the presence of APOBEC3G, even when Vif was expressed,
and it stopped HIV-2 infection in the presence of SAMHD1 and Vpx. Consistent with these findings, MLN4924 prevented
Vpx-mediated depletion of SAMHD1 in macrophages infected with Vpx-expressing HIV-2, as well as HIV-1 Vif-mediated
destruction of APOBEC3G. It also stemmed Vpr-mediated UNG2 elimination from cells infected with HIV-1.
Conclusions: Neddylation plays an important role in HIV-1 and HIV-2 infection. This observation is consistent with the
essential parts that cullin-based ubiquitin ligases play in overcoming cellular anti-viral defenses.
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Retroviruses and their hosts carry evidence of enduring
conflicts. Where hosts evolved antiviral restrictions, viruses
developed countermeasures. Stalemates are reached and
broken as balances between host and virus fall into disequi-
librium. The antiviral restrictions have been found to act
through various distinct mechanisms to block the infecting
virus or to cripple its progeny. HIV, through specialized
proteins, can commandeer cellular ubiquitin ligases to neu-
tralize these blocks to infection.
HIV and SIV infections are restricted in macrophages,
dendritic cells and resting CD4+ T-cells by SAMHD1,
a dGTP-regulated deoxynucleotide phosphohydrolase (rev-
iewed in [1]). SAMHD1 acts indirectly on incoming virus
by depleting the nucleotide pool that is required for reverse
transcription. HIV-2 and some simian immunodeficiency* Correspondence: deNoroC@mail.amc.edu
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reproduction in any medium, provided the orviruses (SIV) express Vpx to recruit SAMHD1 to the
CRL4 complex and thereby trigger its ubiquitination and
subsequent proteasomal degradation [2,3]. Of note, Pertel
et al. identified another restriction distinct from SAMHD1,
but also countered by Vpx [4]. DCAF1 is dispensable for
this function. It's not clear however whether the remainder
of the CRL4 complex is required for the viral defense [4].
HIV-specific restrictions, in addition to blocking virus
on its way into cells can also sabotage virus during produc-
tion. Members of the APOBEC protein family can diminish
the infectivity of viruses produced in their presence [5].
APOBEC3G, a cytidine deaminase, targets residues in nas-
cent negative strands during reverse transcription, resulting
in the accumulation of G to A transitions in viral coding
sequences. APOBEC3G can also physically block reverse
transcription [6,7]. The anti-HIV activity of APOBEC3G
requires its incorporation into virions during virus produc-
tion. APOBEC3G is defeated by the viral Vif protein which
acts as an adaptor between it and the cellular CUL5-
Elongin B/C ubiquitin ligase complex [8]. This promotestral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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struction of APOBEC3G and thus its clearance from virus
producer cells [8,9].
The viral defenses against innate host restrictions dis-
cussed here have two common features. First, all rely on
host ubiquitin ligases. Second, the ubiquitin ligases en-
gaged by these viruses are all thought to rely on neddyla-
tion to activate their function [10].
Neddylation is the addition of NEDD8, an 81–amino
acid protein side-chain that is 60% identical and 80%
homologous to ubiquitin, to a protein [11,12]. NEDD8,
like ubiquitin, is ligated to lysine residues. This modifica-
tion activates cullin ubiquitin ligase function by altering
the conformation of the cullin protein [10].
The neddylation pathway is similar to that of ubiquiti-
nation. NEDD8 is activated by the neddylation activating
enzyme 1 (NAE1) through an ATP dependent process.
This results in the formation of NEDD8-AMP which is
then linked with NAE1 through a thioester bond (reviewed
in Brownell et al. [13]). NEDD8 is subsequently transferred
to one of two E2 enzymes, UBC12 or UBE2F. These en-
zymes dock with an E3 ligase complex, which provides
additional substrate specificity. UBC12 neddylates CUL1
through 4, while UBE2F neddylates CUL5 [14].
Here, we test the impact of neddylation on HIV infection
and on HIV functions mediated through cullin-dependent
ubiquitin ligases. In this work we inhibited neddylation
using either MLN4924 [15] or a dominant negative form
of the NEDD8-conjugating enzyme UBC12 (UBE2M).
MLN4924 is an adenosine sulfamate derivative that forms
an inhibitory NEDD8-AMP mimetic [13]. The dominant
negative UBC12, with a C111S mutation, becomes stably
conjugated to- and thereby sequesters NEDD8 before it
can be transferred to CUL4 [16]. All cullin-containing ubi-
quitin ligases appear to rely on neddylation for efficient
function. In this work we employed specific scenarios to
link the requirement for neddylation with specific HIV
functions.
We hypothesized that without efficient neddylation of
cullin ubiquitin ligases, HIV-1 infection would be blocked
in the presence of APOBEC3G. We further hypothesized
that HIV-2 infection of macrophages would be severely
hindered because Vpx would no longer trigger degradation
of SAMHD1 to rescue reverse transcription. Finally we pos-
ited that HIV-1 Vpr would not trigger UNG2 degradation
or other CRL4-dependent functions. The multi-faceted reli-
ance of HIV on cullin-based ubiquitin ligases suggests that
neddylation could be a strong therapeutic target.
Results
The neddylation inhibitor MLN4924 blocks HIV-2 infection
of primary human monocyte-derived macrophages
HIV-1 Vpr and HIV-2/SIV Vpr and Vpx all engage
CRL4 complexes [17-20]. Vpx from HIV-2 and SIV boostsinfection of primary myeloid-derived cells [18-21], and
has been shown to act through the CRL4 complex in this
capacity [18-20]. We therefore hypothesized, that HIV-2
infection of macrophages would be inhibited in the pres-
ence of MLN4924 if neddylation is important for CRL4
function in this capacity. We based this on previous
observations that Vpx triggers depletion of SAMHD1
through CRL4 [2,3,21] and that neddylation activates
cullin-containing ubiquitin ligase complexes (reviewed
in [10]). Vpx could alternatively use the complex with-
out activation. Further, Hrecka et al. [22] showed that
HIV-1 Vpr causes a boost in CUL4A neddylation. We
thus considered the possibility that Vpx increases ned-
dylation in an NAE1-independent mechanism that’s re-
sistant to MLN4924.
To test whether Vpx-facilitated macrophage infection
can be blocked by MLN4924, we infected primary human
monocyte-derived macrophages (MDMs) with HIV-2 or
HIV-2 with a frame-shift mutation in Vpx, Vpr or both.
All of the viruses used were VSV-G-pseudotyped and ex-
pressed GFP in place of Nef, allowing infected cells to be
identified using flow cytometry. One culture in each infec-
tion type was treated with MLN4924 and the other was
exposed to the same conditions in the absence of the drug.
As expected from previously published data, we ob-
served robust infection with the viruses expressing Vpx
and comparatively modest infection with the viruses lack-
ing the capacity to express Vpx (Figure 1A, c and g versus
e and i, and C). Addition of the neddylation inhibitor re-
duced infection of Vpx-expressing viruses to levels com-
parable with those lacking the capacity to express Vpx
(Figure 1A, c and d, g and h, and C). While infection levels
with Vpx(−) virus were relatively low, they were further re-
duced by MLN4924-treatment (Figure 1A, e and f, i and j,
and C). It’s possible that the additional reduction in Vpx(−)
virus infection is due to another requirement for cullin-
containing ubiquitin ligases or due to an off-target effect
on MDMs at this dose. If the MLN4924-mediated block of
infection is due to the anti-viral activity of SAMHD1, we
hypothesized that an equal dose of this compound would
not block HIV-2 infection in HEK293T cultures. SAMHD1
does not exhibit anti-viral activity in this cell-type regard-
less of whether Vpr or Vpx is absent (Figure 1B, c and g
versus e and i, and D). Addition of MLN4924 did not alter
the overall pattern of infection in any of the cultures
(Figure 1B left column versus right column). Slightly
fewer cells were observed to be infected in the presence
of the drug but this did not correlate with the presence
of Vpx. Of note, we will show in subsequent figures that
MLN4924 is biologically active in HEK293T cells at the
dose used here and that the dose of MLN4924 used in
these experiments has no significant impact on cell health
during the time-frame of the experiments (Additional
file 1: Figure S1).
Figure 1 MLN4924 inhibits infection of macrophages by HIV-2. Primary human MDMs (A) or HEK293T cells (B) were pre-treated with 1 μM
MLN4924 for three hours, and infected at an equivalent MOI with VSV-G-pseudotyped HIV-2 or HIV-2 with a frame-shift mutation in Vpx, Vpr or
both as indicated. Panels C and D summarize data from multiple experiments and error bars show standard error. All viral constructs expressed
GFP in place of Nef. GFP expression was detected using flow cytometry and used as an indicator of infection. The two-tailed Student’s t-test was
used to determine whether differences between pairs of conditions are statistically significant. ns indicates comparisons where the differences
were not significant at a level of 0.05.
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of SAMHD1
We hypothesized that fewer macrophages were in-
fected in the presence of the neddylation inhibitorMLN4924 because HIV-2/SIV requires the function
of the CRL4 ubiquitin ligase to deplete SAMHD1.
Vif should not play a role in the infections tested
because the virus was produced in HEK293T cells
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Vpx acts through the CRL4 complex, we tested the
impact of MLN4924 on the neddylation status of
CUL4A (Figure 2A).
HEK293T cells were transfected with either empty
vector (pcDNA3.1(−)) or with a FLAG–CUL4A expres-
sion construct. The cultures were then either mock- or
MLN4924-treated for four hours. The cells were lysedFigure 2 Inhibition of neddylation blocks Vpx mediated depletion of
for FLAG–CUL4A or empty expression vector (pcDNA3.1(−)), and either trea
harvest. Proteins were isolated from the cell lysates using beads coated wit
FLAG epitope as indicated (A). Monocyte derived macrophages (B) or PMA
mock treated and infected with VSV-G-pseudotyped HIV-1, HIV-1 with a fra
Vpx, Vpr or both. Cells were harvested and the lysates immunoblotted for C
cells were mock treated or treated with increasing concentrations of MLN4
were analyzed by western blotting as indicated (D). HEK293T cells were tra
expression of dominant negative (DN) UBC12 and infected with VSV-G-pse
harvested and immunoblotted for CUL4A, tubulin, SAMHD1, UBC12 and HIand proteins were isolated with FLAG-specific antibody to
purify exogenously-produced FLAG–CUL4A. Immuno-
blotting with NEDD8-specific antibody showed a band
only in the isolates from the cultures transfected with
FLAG–CUL4A expression vector that were not treated
with MLN4924 (Figure 2A). This band co-migrated with
the upper band of the doublet detected with the FLAG-
specific antibody which detects exogenously producedSAMHD1. HEK293T cells were transfected with an expression vector
ted with 250 nM MLN4924 or mock treated for four hours before
h FLAG-specific antibody, and immunoblotted for either NEDD8 or the
-differentiated THP1 cells (C) were treated with 1 μM MLN4924 or
me shift mutation in Vpr, HIV-2 or HIV-2 with a frame-shift mutation in
UL4A, β-actin, SAMHD1, and HIV p24/p27. PMA differentiated THP1
924 before infection with HIV-2. Cells were harvested and the lysates
nsfected with either an empty expression vector (vector) or one for
udotyped HIV-2 or HIV-2 with a frame-shift mutation in Vpx. Cells were
V p24/p27 (E).
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was detected with the NEDD8 antibody and only a single,
faster-migrating band was detected with the FLAG-specific
antiserum. These results confirm that the upper band of
the doublet is the neddylated CUL4A species and that
MLN4924 blocks CUL4A neddylation.
After establishing that MLN4924 interferes with
neddylation of CUL4A, we determined whether the
compound blocks Vpx-mediated SAMHD1 depletion.
Primary human monocyte-derived macrophages or PMA-
differentiated THP1 cells were either mock- or MLN4924-
treated. The cultures were then mock-infected or infected
with HIV-1, Vpr-deficient HIV-1, HIV-2, or HIV-2 that
cannot express Vpx, Vpr or both (Figure 2 panels B and C).
Both cell types, when treated with the inhibitor, showed
the collapse of the neddylated form of CUL4A into a
single band, indicating that the neddylated form of CUL4A
was no longer present. In the absence of MLN4924,
SAMHD1 was markedly depleted in samples infected with
Vpx-encoding HIV-2. Treatment with MLN4924, however
maintained SAMHD1 levels despite infection with Vpx-
encoding HIV-2. This occurred in both MDM and THP1
cultures. These data demonstrate that MLN4924 mediated
inhibition of neddylation blocks HIV-2 Vpx-triggered
SAMHD1 degradation.
In order to determine the minimal MLN4924 dose
that’s required to block neddylation and Vpx-mediated
SAMHD1 degradation in PMA-differentiated THP1 cells,
we titrated the drug in 100 nM increments (Figure 2D).
One hundred nanomolar MLN4924 was sufficient to cause
a loss of the upper band that represents neddylated
CUL4A. The loss of neddylation was accompanied by an
intensification of the lower band. SAMHD1 levels only in-
creased in 200 nM or greater concentrations of MLN4924,
suggesting that there may be residual neddylation, and ac-
tivity, at 100 nM that we did not readily detect by western
blotting.
Dominant negative (DN) NEDD8 E2 ligase UBC12 pro-
vides an alternate means for blocking cullin neddylation
[16]. Rather than blocking at the level of the E1 NEDD8
ligase, it sequesters NEDD8 at the level of the E2 ligase.
Expression of dominant negative DN UBC12, like MLN
4924, reduced the fraction of neddylated CUL4A in HEK
293T cells (Figure 2E), albeit not as efficiently as the drug.
The CUL4A bands shifted from a lighter doublet to a dar-
ker lower band in DN UBC12-expressing cells, much as
with MLN4924 treatment. Further, the decrease in neddy-
lated CUL4A was accompanied by a marked decrease in
SAMHD1 depletion. HEK293T cells were used for these
experiments because they are readily transfectable, unlike
either THP1 cells or MDMs. Overall this data supports
our observation that neddylation is important for Vpx-
mediated SAMHD1-depletion regardless of whether it’s
blocked with DN UBC12 or with MLN4924.Vif-induced depletion of APOBEC3G and efficient infectivity
in the presence of APOBEC3G both rely on neddylation
Recent work by Stanley et al. showed that blocking the
neddylation cascade hinders Vif-mediated depletion of
APOBEC3G and thus infectivity in the presence of this
cellular antiviral defense [23]. Here we confirm and sup-
port those earlier findings using a different system and
demonstrate that neddylation is required for efficient Vif-
mediated elimination of APOBEC3G. Based on the previ-
ous work, we hypothesized that inhibition of neddylation
would block Vif-mediated depletion of APOBEC3G in
virus producing cells. Virus from cultures treated with
MLN4924, regardless of whether the viral genome en-
codes Vif, would thus package APOBEC3G and fail to effi-
ciently infect target cells.
To test this, HEK293T cells were transfected with an
expression vector for C-terminal HA epitope-tagged
APOBEC3G and either empty pcDNA3.1(−) expression
vector, a Vif expression vector pNL-A1 or pNL-A1Δvif
which is isogenic with pNL-A1 but does not express Vif.
Expression of Vif, as expected, dramatically reduced the
levels of APOBEC3G-HA (Figure 3A). Treatment with
MLN4924 blocked Vif-mediated APOBEC3G depletion
and allowed packaging of APOBEC3G into virions iso-
lated from the culture supernatant (Figure 3B).
Infectivity, measured by GHOST cell assays, showed
that virus produced in the presence of MLN4924, but in
the absence of APOBEC3G, was unaffected whereas treat-
ment with MLN4924 in the presence of APOBEC3G, re-
sulted in a substantial reduction in infectivity (Figure 3C
and D). Taken together, these data indicate that neddyla-
tion is required for Vif-mediated APOBEC3G degradation
and that treatment of producer cells with MLN4924 re-
sults in APOBEC3G incorporation into virions and a sub-
sequent loss of infectivity.
HIV-1 Vpr-mediated degradation of UNG2 is
neddylation-dependent
We and others have shown that UNG2 is a target for
Vpr-directed degradation through the CRL4 complex
[24,25]. Based on previous observations that neddylation
activates cullin-dependent ubiquitin ligases, we hypothe-
sized that this modification is required for efficient Vpr-
mediated UNG2 degradation. If this is true, then a decrease
in CUL4A neddylation should correlate with reduced Vpr-
dependent protein depletion through CRL4. We thus tested
whether MLN4924 blocks Vpr-dependent UNG2 depletion.
Infection of HEK293T cells with Vpr-expressing HIV-1
caused a dramatic decrease in endogenous UNG2 levels
(Figure 4A, endog.). Surprisingly, application of MLN4924
after infection barely blocked UNG2 depletion in these
cultures. The observation that endogenous UNG2 deple-
tion was not blocked more completely despite the robust
loss of neddylated CUL4A species, led us to hypothesize
Figure 3 MLN4924 inhibits Vif function. HEK293T cells were transfected with an expression vector for APOBEC3G–HA, and either empty vector,
pNL-A1, or pNL-A1Δvif. Twenty four hours later, the cells were either mock treated or treated overnight with 1 μM MLN4924. Cells were then harvested
and immunoblotted for the HA epitope, β-actin, or HIV-1 p24 (A). HEK293T cells were co-transfected with an expression vector for APOBEC3G-HA and
either an expression vector for HIV-1 or one for a Δ vif HIV-1 along with an expression vector for the vesicular stomatitis virus glycoprotein (VSV-G).
Twenty four hours later, cells were either mock treated or treated with 1 μM MLN4924, and cultured overnight. Virus-containing supernatants were
collected and immunoblotted for HIV-1 p24 and the HA epitope (B). HEK293T cells were co-transfected with HIV-1 or Δvif HIV-1 constructs along with
an expression vector for VSV-G and either empty vector or APOBEC3G–HA. Twenty four hours later, cells were either mock treated or treated with
1 μM MLN4924, and left overnight. The virus-containing supernatants were collected and used to infect GHOST cells. Twenty four hours post infection;
the cells were harvested, fixed, and analyzed for GFP expression by flow cytometry (C). Panel D summarizes data from multiple experiments performed
as indicated for panel C and error bars show standard error. The two-tailed Student’s t-test was used to determine whether differences between pairs
of conditions are statistically significant. ns indicates comparisons where the differences were not significant at a level of 0.05.
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NEDD8-dependent and -independent mechanisms. The lat-
ter could be mediated through a cullin-independent ubiqui-
tin ligase that is not impacted by a neddylation block, or byanother mechanism altogether. Langevin et al., for example,
showed that Vpr expression hinders UNG2 production at
the level of transcription [26]. Indeed, when we expressed
UNG2, tagged with dual HA epitope tags (UNG2–2HA)
Figure 4 Neddylation is important for Vpr mediated depletion of UNG2 through CRL4. HEK293T cells were either mock treated or treated
with 250 nM MLN4924 for four hours and infected with VSV-G-pseudotyped-HIV-1 or -HIV-1 with a frame shift mutation in Vpr. Twenty-four hours
after infection, cells were harvested and the lysates immunoblotted for endogenous UNG2, HIV-1 p24 and tubulin (A endog.). HEK293T cells were
transfected with an expression vector for UNG2 with two HA epitope tags (UNG2–2HA). Forty-eight hours later, cultures were mock treated or
treated with 250 nM MLN4924 for four hours and then infected with VSV-G-pseudotyped-HIV-1 or -HIV-1 with a frame shift mutation in Vpr.
Twenty-four hours later, cells were lysed and immunoblotted for the HA epitope, HIV-1 p24, and tubulin (A exog.). HEK293T cells were treated for
2 hours with concentrations of MLN4924 as indicated and then either mock infected or infected, in parallel, with a reduced MOI (approximately
2) of VSV-G-pseudotyped HIV-1. The cells were harvested for immunoblotting 24 and 48 hrs after infection. Blots were probed for endogenous
UNG2, CUL4A, tubulin or HIV-1 p24 (B). Twenty-four hours after transfection with UNG2–2HA expression vector, HEK293T cells were treated and
infected as described for panel B. Forty-eight hours after infection, cultures were harvested for western blot analysis and probed for UNG2–2HA
(HA), CUL4A, HIV-1 p24, or tubulin (C). HEK293T cells were transfected with UNG2–2HA expression vector and either an expression vector
(pcDNA3.1(−)) or ones for DN UBC12 or DN CUL4A. Twenty-four hours later cultures were mock infected or infected with VSV-G-pseudotyped-HIV-1.
Twenty-four hours after infection cultures were lysed for immunoblotting and probed for UNG2–2HA (HA), endogenous UNG2, CUL4A, DN CUL4A
(HA), DN UBC12, HIV-1 p24, or tubulin (D).
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UNG2–2HA levels were maintained upon infection with
HIV-1 in the presence of MLN4924 (Figure 4A, exog.).
We tested the kinetics of endogenous UNG2 deple-
tion, hypothesizing that Vpr coming in with the virion
relies on CRL4-mediated UNG2 depletion while Vpr ex-
pressed from proviruses acts to silence transcription. We
again used HEK293T cultures because we could look at
both endogenous and exogenous UNG2. At 24 hours
post infection we saw preservation of UNG2 with as lit-
tle as 100 nM MLN4924, whereas at 48 hrs after infec-
tion we saw little preservation of UNG2 even at much
higher concentrations of the drug (Figure 4B). We also
tested exogenously expressed UNG2–2HA in this assay
and found that while infection with Vpr-expressing HIV-1
caused UNG2—2HA depletion, MLN4924 treatment main-
tained UNG2—2HA at levels comparable to those in
mock-infected cells in as little as 100 nM drug at 48 hrs
post infection (Figure 4C). Interestingly, as we increased
MLN4924 concentrations in cultures expressing exogenous
UNG2–2HA we observed a decrease in p24 levels. This
was not seen in cells expressing only endogenous UNG2(Figure 4B). The decrease in p24 could reflect an anti-viral
property of UNG2 when it’s over-expressed in the absence
of either constitutive or Vpr-mediated turn-over.
We again used DN UBC12 to confirm that our observa-
tions did not rely solely on MLN4924. Here, we transfected
HEK293T cells with expression vector for UNG2‒2HA
either with empty vector, vector encoding DN UBC12 or
vector encoding DN CUL4A (a truncated CUL4A that
lacks the C-terminus, including the neddylation site). The
cells were then either mock-infected or infected with HIV-1.
Here both DN UBC12 and DN CUL4A boosted steady
state UNG2 levels. This is consistent with our previous
work showing that UNG2 is constitutively turned over
through the CRL4 complex, albeit to a lesser degree than
in the presence of Vpr [24]. Here both exogenous UNG2–
2HA and endogenous UNG2 were depleted upon infection
however only the depletion of the exogenous protein was
blocked by DN CUL4A and DN UBC12 (Figure 4D).
HIV-1 Vpr aids macrophage infection [27-29], however
it does not deplete SAMHD1 in the context of an infec-
tion (Figure 2). We therefore tested whether inhibition of
neddylation would interfere with HIV-1 infection of THP1
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entiated THP1 cells with equivalent titers of VSV-G-
pseudotyped env-deficient pNL4-3 that encoded (pNL4-3)
or failed to encode Vpr (pNL4-3Δvpr) in the presence or
absence of MLN4924. Vpr had no detectable impact on
HEK293T infection (Figure 5A). Treatment with MLN4924,
as in our other experiments, reduced infection slightly.
Vpr caused a significant but modest increase in infection
in PMA-differentiated THP1 cells, and this gain was neu-
tralized in the presence of MLN4924 (Figure 5B and C).
Interestingly, the infectivity of Vpr-deficient virus was
reduced by about half in the presence of MLN4924
(Figure 5B and C).
Discussion
Cullin4A and cullin5 are required for HIV to counteract at
least two well-characterized antiviral factors, SAMHD1 and
APOBEC3G. Neddylation is important for the function of
ubiquitin ligases that rely on cullin proteins but the role of
this modification is only now being tested in the context
of HIV infections. Here we found that when neddylation
was impaired either pharmacologically or by interference
with the neddylation pathway though expression of a dom-
inant negative UBC12, HIV-2 was no longer able to deplete
SAMHD1. Inhibition of neddylation similarly blocked HIV-1
Vif-mediated reduction of APOBEC3G levels. As expected,
interfering with Vpx and Vif function thus blocked HIV inFigure 5 MLN4924 inhibits HIV-1 infection of PMA-differentiated THP
pre-treated with 1 μM MLN4924 for three hours, and infected at an equiva
All viral constructs expressed GFP in place of Nef. Forty-eight hours post infec
GFP-expressing cells using flow cytometry. Panel C summarizes data from mu
bars show standard deviation. The two-tailed Student’s t-test was used to det
significant. ns indicates comparisons where the differences were not significacontexts where these viral defenses were required for effi-
cient infection. Neddylation thus plays a critical role in
HIV biology and could present a target for antiviral inter-
vention to block multiple viral functions simultaneously.
The limitation to using a compound like MLN4924
therapeutically is however its potential for affecting all
cullin-dependent ubiquitin ligases.
Vpx-mediated depletion of SAMHD1 showed a clear
reliance on neddylation in primary human monocyte-
derived macrophages, in differentiated THP1 cells and in
HEK293T cells. Interestingly however, endogenous UNG2
levels were not well maintained when cultures were in-
fected with Vpr-expressing HIV-1 in the presence of
MLN4924. Vpr-mediated UNG2 depletion through CRL4
is a well-established phenotype [24,25,30]. Vpr assembles
with both UNG2 and with the CRL4 complex and aids the
assembly of UNG2 with the CRL4 complex [24,25]. While
Vpr is not required for the depletion of UNG2 through
CRL4, Vpr enhances this function [24]. Langevin et al.
further showed that Vpr has a negative effect on the
promoter of UNG2, but not on that of UNG1 [26]. In-
hibition of neddylation should block constitutive and
Vpr-mediated turnover of UNG2 like it blocked deple-
tion of SAMHD1 and APOBEC3G, but shouldn’t interfere
with Vpr-mediated inhibition of UNG2 transcription. In-
deed, when we expressed UNG2—2HA from a CMV-IE
promoter we observed depletion of this protein upon1 cells. HEK293T cells (A) or PMA differentiated THP-1 cells (B) were
lent MOI with env(−), VSV-G-pseudotyped-HIV-1 or -HIV-1 lacking Vpr.
tion, cells were fixed, and infectivity was determined by enumerating
ltiple replicates of experiments performed as indicated for panel B. Error
ermine whether differences between pairs of conditions are statistically
nt at a level of 0.05.
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with the neddylation inhibitor. It is likely that infection
with a Vpr-expressing virus in the presence of MLN4924
thus interferes with endogenous UNG2 predominantly at
the transcriptional level but not at the level of CRL4-
directed depletion. These observations appear to separate
the two mechanisms of UNG2 depletion by HIV-1 Vpr
and show that both may be at play after an infection.
The role of UNG2 is not clear. Some work shows a nega-
tive impact of UNG2 on infection [30], other work shows a
positive role [31-33], or no apparent effect [34,35]. The fact
that HIV-1 Vpr employs two distinct mechanisms to re-
duce UNG2 levels suggests that UNG2 may be detrimental
to the virus and establishes that Vpr, while being a relatively
small protein, can block protein production at two points.
We did not observe a generalized Vpr expression-in
duced boost in the levels of CUL4 neddylation (Figure 2B
and C) as might be expected based on the observations of
Hrecka et al. [22]. This difference is not due to the use of
primary hMDMs or THP1 cells because we saw the same
level of neddylation in HEK293T cells infected with virus
with or without Vpr (Additional file 2: Figure S2). The key
differences between work shown here and that presented
by Hrecka et al. is that we used infection to initiate Vpr ex-
pression rather than transfection of a Vpr expression vector
and that we did not exogenously express components of
the CRL4 complex. Our observation that UNG2 can as-
semble with CRL4 in the absence of Vpr [24] suggested
that Vpr is boosting the efficacy of this interaction. The
mechanism was unknown so increased neddylation was an
attractive candidate. Our subsequent work however sup-
ports a model where Vpr is either recruiting or retaining
more of the target proteins at the ubiquitin ligase [17].
HIV-1 Vpr also promotes G2 cell cycle arrest though
interaction with the CRL4 ubiquitin ligase complex
[17,22,36-39]. G2 cell cycle arrest is not linked to HIV-1
Vpr mediated UNG2 depletion and the ubiquitination
target responsible for inducing arrest is not known [40].
While working to determine whether MLN4924 blocks
Vpr-mediated G2 arrest we found that treating HEK293T
cells with this agent blocked cells with a 4n complement
of DNA suggesting that they were in either G2 or early
mitosis (Additional file 3: Figure S3). This phenotype is
likely because cullin-based ligases are required to maintain
the delicate balance of cell cycle control proteins. This cell
cycle block did not interfere with our analyses of protein
depletion because cells under all infection conditions were
treated with the drug prior to infection. Further, in our
SAMHD1 experiments we worked predominantly with
terminally differentiated and thus non-cycling cells.
Finally, recent work by de Silva et al. showed that Vpr
enhances infection of monocyte derived dendritic cells
with both single-round and replication competent virus
[41]. This effect does not require DCAF1 and is thusthought to be independent of the CRL4 complex. This
data is consistent with our THP1 infection data from
Figure 5. The effects that we observed were relatively
modest and will thus require additional experiments to de-
termine whether CRL4 and other cullin-based ubiquitin li-
gases are dispensable for the Vpr-mediated infection boost.Conclusions
The work presented here demonstrates that neddylation is
required for HIV to overcome at least two anti-viral restric-
tions and Vpr-mediated depletion of UNG2 through the
CRL4 complex. The findings thus highlight the possibility
of targeting neddylation for the development of therapeutic
interventions against HIV infection.
Of note, while this manuscript was under revision
Hofmann et al. published work showing that neddylation
is important for Vpx-mediated depletion of SAMHD1 [42].Methods
Ethics statement
Primary human monocytes were obtained from de-iden
tified donors at the University of Nebraska Medical Center,
Omaha, NE. The Albany Medical College Committee on
Research Involving Human Subjects approved our protocol
for the use of primary human monocytes and granted a cat-
egory 4 exemption from consent procedures based on the
anonymous nature of the samples.Cell lines
HEK293Tand GHOSTcells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) with 10% fetal bovine
serum, supplemented with 100 U/mL of penicillin, 100 μg/
mL of streptomycin, and 2 mM L-glutamine.
Monocytic THP1 cells were differentiated using PMA
treatment and cultured in RPMI 1640 with 10% fetal bo-
vine serum, supplemented with 100 U/mL of penicillin,
100 μg/mL of streptomycin, and 2 mM L-glutamine.
Elutriated monocytes were obtained from de-identified
donors (University of Nebraska Medical Center, Omaha,
NE) and differentiated by treatment with recombinant hu-
man macrophage colony stimulating factor (rhM-CSF, Cell
Sciences, Canton MA) in DMEM with 10% human serum
for one week. Subsequently, the monocyte derived macro-
phages were cultured in DMEM supplemented with 10%
human serum.
All cells were maintained at 5% CO2 at 37°C.Pharmacological inhibitor MLN4924
MLN4924 was a kind gift of Millennium Pharmaceuti-
cals. The dry compound was dissolved in water at a con-
centration of 1 mM, and diluted as indicated.
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The pNL-A1 and pNL-A1-ΔVif plasmids were a kind
gift from Dr. K. Strebel [43]. Molecular cloning of
APOBEC3G‒HA was previously described in Stopak et al.
[9]. The cloning of UNG2-2HA was previously described
in Wen et al. [24]. The dominant negative UBC12 expres-
sion plasmid was a kind gift from Dr. T. Kamitani [16]. The
FLAG‒CUL4A plasmid was a kind gift from Dr. J. Jin [44].
The Dominant negative CUL4A expression vector was
described in Wen et al. [17].
Cells were transfected using the calcium phosphate
method.
Immunoprecipitations
HEK293T cells were transfected with either empty vector
(pcDNA3.1(−)) or an expression vector encoding FLAG
epitope-tagged cullin4A. Four hours before harvest, cells
were treated with 250 nM MLN4924 or mock treated.
Forty-eight hours after, cells were lysed in 0.5 mL ELB
(50 mM HEPES, pH 7.3, 400 mM NaCl, 0.2% Nonidet
P-40, 5 mM EDTA, 0.5 mM dithiothreitol, and Complete™
protease inhibitor mixture (Roche Applied Science, as per
supplier’s instructions)) at 4°C for 30 min, then centrifuged
to remove cellular debris. The supernatant was incubated
with FLAG-specific M2 agarose resin overnight (Sigma-
Aldrich). The resin-bound proteins were then washed three
times with 1 ml of ELB buffer, and bound proteins were
eluted using a 200 μg/mL solution of FLAG peptide
(Sigma-Aldrich). The eluted proteins were immunoblotted
for NEDD8 or for the FLAG epitope as indicated.
Viral stocks and infections
The proviral clones used in the APOBEC3G experiment
(pNL4-3nef(−)::HSAenv(−),HIV-1; mouse HSA replaces
Nef and pNL4-3nef(−)::HSAenv(−) vif (−), mouse HSA
replaces nef ) were a kind gift of Dr. M. J. Lenardo [45].
The proviral clones used in the UNG2 depletion experi-
ment (pNL4-3GFPenv(−)nef(−) and pNL 4–3 GFPenv(−)
vpr(−)) were a kind gift of Dr. V. Plannelles [46].
The proviral clones used in the experiments with HIV-2
originated as a kind gift of Dr. M. Fujita, but have GFP
in place of nef sequences upstream of the 3’ LTR. GFP
encoding HIV-2 is based on pGL-AN, HIV-2Vpx(−) on
pGL-St, HIV-2Vpr(−) on pGL-Ec, and HIV-2Vpx(−)Vpr
(−) on pGL-St/Ec [47].
To generate viral stocks, the proviral clones were co-
transfected with an expression construct for vesicular
stomatitis virus G–protein (VSV-G) into HEK293T cells
using the calcium phosphate method. The virus was har-
vested 48 hours after transfection.
Immunoblotting
Harvested proteins were separated by SDS-PAGE, trans-
ferred onto a PVDF membrane (Millipore), and thenprobed with the indicated primary antibodies. The pri-
mary antibodies used were anti-FLAG: M2 (F1804, Sigma-
Aldrich), anti-tubulin: (N-356 Amersham), anti-β actin
(A5441, Sigma-Aldrich), anti-HA (12CA5, Roche), anti-
UNG2 (a kind gift from Dr. Geir Slupphaug), anti-SAM
HD1 (GTX83687, GeneTex), anti-CUL4A: (#2699S, Cell
Signaling), and anti-UBC12: (#5641S, Cell Signaling).
Please note that the UBC12 antibody also recognizes
DN UBC12. The following reagents were obtained through
the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: HIV-1 Vif Monoclonal
Antibody (#319) (from Dr. Michael H. Malim, [48-50]),
the p24 hybridoma supernatant (183-H12-5C) (from Drs.
Bruce Chesebro and Hardy Chen [51]) and HIV-1 Vpr
(1–50) Antiserum (from Dr. Jeffrey Kopp).
Cell viability assay
PMA-differentiated THP-1 cells or HEK293Tcells were either
mock treated, treated with 1 μM MLN4924, or 5 μg/mL
puromycin for 24 hours. Cell viability was assessed using
the Cell Counting Kit 8 (Dojindo Molecular Technologies,
Inc) according to the manufacturer’s protocol.
Additional files
Additional file 1: Figure S1. HEK293T and THP1 cultures treated with
1 μM MLN4924 exhibit metabolic activity similar to those of solvent-treated
cultures. Cultures of PMA-differentiated THP1 or HEK293T cells were treated
with solvent, 1 μM MLN4924 or 5 μg/mL puromycin for 24 hours. Cell viability
was tested by measuring dehydrogenase activity as reflected by cleavage of
WST-8 formazan reagent. Error bars represent +/− SE.
Additional file 2: Figure S2. Vpr does not increase the neddylation of
CUL4A. HEK293T cells were either mock treated or treated with 500 nM
MLN4924 for 30 minutes and then infected with VSV-G-pseudotyped HIV-1 or
HIV-1 with a frame shift mutation in Vpr. Twenty four hours after infection, cells
were harvested and immunoblotted for CUL4A, tubulin, HIV-1 p24 or Vpr.
Additional file 3: Figure S3. MLN4924 causes cell cycle arrest in
HEK293T cells. HEK293T cells were either mock treated or treated with
500 nM MLN4924. Twenty-four hours post-treatment; the cells were
harvested and the DNA was stained with propidium iodide. Cellular DNA
content was assessed by flow cytometry.
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